&Partners’s Mesoblast MESO Stock Holding History

&Partners’s Portfolio MESO Stock Details MESO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$414K	Buy	26,946 +8,434	+46%	+$140K	﹤0.01%	1804
2025 Q4	$334K	Buy	+18,512	New	+$319K	﹤0.01%	1852

Other funds holding MESO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Penbrook Management New York $132M AUM 29.91% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

&Partners's MESO Position: Q1 2026 in Review

&Partners increased its Mesoblast (MESO) stake by 46% in Q1 2026, buying an estimated $140K and bringing the position to 26,946 shares worth $414K. The position accounts for ﹤0.01% of the portfolio, ranked #1804.

&Partners first reported a position in MESO in Q4 2025 and has held it in 2 quarters since. 69 funds tracked by Wall St. Rank hold MESO as of Q1 2026.

&Partners held 26,946 shares of Mesoblast worth $414K as of Q1 2026.
&Partners bought 8,434 Mesoblast shares in Q1 2026, an estimated $140K.
Mesoblast made up ﹤0.01% of &Partners's portfolio in Q1 2026, its #1804 holding.
&Partners first reported a position in Mesoblast in Q4 2025 and has held it in 2 quarters since.
69 funds tracked by Wall St. Rank held Mesoblast as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.